Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
138 studies found for:    Vidarabine | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Leukemia, Myeloid, Acute
Interventions: Drug: busulfan;   Drug: fludarabine phosphate;   Radiation: total-body irradiation (TBI);   Procedure: Stem cell transplant;   Drug: cyclophosphamide;   Drug: tocilizumab
2 Recruiting A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Conditions: CLL (Chronic Lymphocytic Leukemia);   SLL (Small Lymphocytic Lymphoma)
Interventions: Drug: Ibrutinib;   Drug: Fludarabine
3 Recruiting Hematopoietic Stem Cell Transplant for Sickle Cell Disease
Conditions: Sickle Cell Disease;   Sickle Cell Anemia;   SCD
Interventions: Drug: Fludarabine;   Procedure: Hematopoietic Stem Cell Transplant (HSCT)
4 Recruiting Fludarabine / Total Body Irradiation Regimen for ALLO HCT in Acute Lymphoblastic Leukemia
Condition: Adult Lymphoblastic Lymphoma
Interventions: Drug: Fludarabine;   Procedure: Total Body Irradiation
5 Recruiting Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant
Conditions: Non Hodgkin's Lymphoma;   Hodgkin Disease;   Multiple Myeloma
Interventions: Other: Fludarabine and total body irradiation;   Radiation: Total body irradiation
6 Recruiting Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant
Condition: Graft Failure
Interventions: Procedure: Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors;   Drug: fludarabine;   Procedure: TBI
7 Recruiting Fluorine F 18 Clofarabine PET/CT in Imaging Patients With Autoimmune or Inflammatory Diseases
Conditions: Autoimmune Disease;   Crohn Disease;   Inflammatory Disorder;   Rheumatoid Arthritis;   Systemic Lupus Erythematosus;   Takayasu Arteritis
Interventions: Procedure: Computed Tomography;   Radiation: Fluorine F 18 Clofarabine;   Procedure: Positron Emission Tomography
8 Recruiting 18F-Clofarabine PET/CT in Imaging Cancer Patients Before and After Interventions
Condition: Malignant Neoplasm
Interventions: Procedure: Computed Tomography;   Radiation: Fluorine F 18 Clofarabine;   Procedure: Positron Emission Tomography
9 Recruiting International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
Condition: Acute Myeloid Leukaemia
Interventions: Drug: Gemtuzumab ozogamicin;   Drug: Liposomal daunorubicin;   Drug: Mitoxantrone;   Drug: Fludarabine;   Drug: Cytarabine;   Drug: Busulfan;   Drug: Cyclophosphamide
10 Not yet recruiting Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia
Conditions: Hematopoietic/Lymphoid Cancer;   Acute Myeloid Leukemia
Interventions: Procedure: Leukapheresis;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Biological: CD33-CAR-T Cell Infusion
11 Not yet recruiting Autologous T-Cells Expressing a Second Generation CAR for Treatment of T-Cell Malignancies Expressing CD5 Antigen
Conditions: T-cell Acute Lymphoblastic Lymphoma;   T-non-Hodgkin Lymphoma;   T-cell Acute Lymphoblastic Leukemia
Interventions: Genetic: CD5.CAR/28zeta CAR T cells;   Drug: Fludarabine;   Drug: Cytoxan
12 Recruiting Treatment of Metastatic Melanoma With TSA-CTL(Tumor Specific Antigen-Induced Cytotoxic T Lymphocytes)
Condition: Metastatic Melanoma
Interventions: Biological: TSA-CTL(Tumor Specific Antigen Induced Cytotoxic Lymphocyte);   Drug: Cyclophosphamide;   Drug: Fludarabine
13 Recruiting Fludarabine Based RIC for Bone Marrow Failure Syndromes
Condition: Bone Marrow Failure Syndromes
Interventions: Other: MRD-BMT with Fludarabine-based RIC for Acquired AA;   Other: MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia;   Other: MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia
14 Recruiting Fludarabine and Cytarabine Versus High-dose Cytarabine for CBF-AML
Conditions: Acute Myeloid Leukemia;   Core-Binding Factor
Interventions: Drug: Fludarabine;   Drug: Cytarabine
15 Not yet recruiting CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)
Conditions: Hodgkin's Lymphoma;   Non-Hodgkin Lymphoma
Interventions: Genetic: CAR T Cells;   Drug: Cyclophosphamide;   Drug: Fludarabine
16 Not yet recruiting Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR)
Condition: Hepatocellular Carcinoma
Interventions: Genetic: GLYCAR T cells;   Drug: Cytoxan;   Drug: Fludarabine
17 Recruiting A Cancer Research UK Trial of Anti-GD2 T-cells (1RG-CART)
Condition: Relapsed or Refractory Neuroblastoma
Interventions: Genetic: 1RG-CART/m^2 (Dose Level 1);   Genetic: 1RG-CART/m^2 (Dose Level 2);   Genetic: 1RG-CART/m^2 (Dose Level 3);   Genetic: 1RG-CART/m^2 (Dose Level 4);   Drug: Cyclophosphamide;   Drug: Fludarabine;   Genetic: 1RG-CART/m^2 (Dose Level 5)
18 Recruiting LY2606368 in Combination With Cytarabine and Fludarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HRMDS)
Condition: Leukemia
Interventions: Drug: Fludarabine;   Drug: Cytarabine;   Drug: LY2606368
19 Recruiting CD19+ CAR T Cells for Lymphoid Malignancies
Conditions: Leukemia;   Lymphoma
Interventions: Drug: Fludarabine monophosphate;   Drug: Cyclophosphamide;   Procedure: T Cell Infusion
20 Recruiting Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm
Conditions: Adult Acute Myeloid Leukemia in Remission;   Donor;   Early Relapse of Acute Myeloid Leukemia;   Late Relapse of Acute Myeloid Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions: Drug: cyclophosphamide;   Biological: Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes;   Other: laboratory biomarker analysis;   Biological: Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes;   Drug: Fludarabine Phosphate

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.